Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NVX-CoV2372 · 1 trial · 2 indications
Antibody concentrations 1 month after the recombinant vaccine booster (V2) in patients with IBD and solid organ transplant recipients compared to their baseline visit (V1).
| Arm | Type | Description |
|---|---|---|
| Participants who have had Solid Organ Transplants | EXPERIMENTAL | Male and females aged 18 to 85 who are solid organ transplant recipients and receive the study intervention. |
| Participants with IBD | EXPERIMENTAL | Male and females aged 18 to 85 who have IBD and receive the study intervention. |
| Name | Type | Description |
|---|---|---|
| NVX-CoV2372 | BIOLOGICAL | Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5 |
Inclusion Criteria: • Patient has a history of ulcerative colitis (UC), Crohn's disease, pouchitis, or indeterminate colitis diagnosed by standard clinical, radiographic, endoscopic, and histopathologic criteria. And / or patient is a solid organ transplant recipient (e.g. lung, kidney, liver) * ...
NVX-CoV2372 is an investigational monoclonal antibody being studied for use in immunosuppressed populations, specifically to evaluate humoral and cell-mediated immunogenicity related to COVID-19. It is being developed as a potential intervention for individuals with immunosuppression, a condition that can weaken the body's immune response to infections.
NVX-CoV2372 is developed by Novavax, Inc., a biotechnology company traded on the Nasdaq under the ticker symbol NVAX. The company is conducting clinical research on this investigational monoclonal antibody for use in immunosuppressed populations.
NVX-CoV2372 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy in immunosuppressed populations.
NVX-CoV2372 has one completed clinical trial, identified as NCT06027229, titled "Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations." This Phase 2 study enrolled 21 participants in the United States and evaluated the drug's immunogenicity in immunosuppressed individuals.
NVX-CoV2372 is a monoclonal antibody, not a vaccine. It is being studied for its ability to generate humoral and cell-mediated immune responses in immunosuppressed populations, potentially offering a different approach to addressing COVID-19 in individuals with weakened immune systems.